RxDoctor Payments Data

Valerie Stanley

Nurse Practitioner · Albany, NYNPI 1689696171

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $36,862 of the $55,214 with a category attached, or 66.8%. Neurelis, Inc. accounts for 94.0% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2023 at $29,673 and has fallen 95.8% since, to $1,247 in 2025. Among nurse practitioner clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$55,214in general payments, 2019–2025

Across 111 payments — averaging $497.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurelis, Inc.$52K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$452
  • Boston Scientific$331
  • Livanova USA, Inc.$326
  • Johnson & Johnson$283
  • AstraZeneca$222
  • plus $2K from 14 others

What the payments were for

  • Speaking & faculty fees$36,86267%
  • Travel & lodging$13,34724%
  • Food & beverage$5,0059%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$55,214 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Other nurse practitioner in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →